Aventis, Baxter Renew Battle Over Hemophilia Drug
In the suit, which was filed Monday in the U.S. District Court in Wilmington, Del., Aventis said that Baxter’s hemophilia drug Advate contained a stabilized solution with Factor VIII activity.
The patent was originally granted in 1996 to what, after many mergers, would become Aventis.
Eventually, it became known that Baxter, a subsidiary of Baxter International Inc.,...
To view the full article, register now.